SS-31

Overview

It's completely reasonable — and intelligent — to be curious about SS-31.

SS-31 (also known as elamipretide; developmental code MTP-131) is a synthetic tetrapeptide developed by Stealth BioTherapeutics. Its unusual and distinguishing feature: selective mitochondrial targeting. The peptide accumulates in the inner mitochondrial membrane at concentrations hundreds of times greater than the cytoplasm, drawn there by electrostatic interaction with the mitochondrial membrane potential.

People researching SS-31 are typically drawn to a specific thesis: if mitochondrial dysfunction is central to aging and to a wide range of diseases, a compound that specifically repairs one of its structural foundations is worth understanding deeply — whether or not any clinical product ever reaches market.

The Science: Cardiolipin and the Shape of Mitochondria

The elegance of SS-31 comes from its target: a phospholipid called cardiolipin.

Cardiolipin lives in the inner mitochondrial membrane, where it shapes the folds (cristae) that hold the electron transport chain. Think of cristae as the scaffolding that keeps the mitochondrion's energy machinery organized and efficient. When cardiolipin becomes oxidized or abnormal — in aging, genetic disease, or stress — the scaffolding collapses, energy production falters, and reactive oxygen species leak out.

SS-31 binds cardiolipin and helps preserve its native conformation:

• Cardiolipin stabilization — SS-31 binds the lipid directly, protecting its shape.
• Preservation of cristae structure — stable cristae support electron transport and ATP output.
• Reduced mitochondrial ROS — with better-organized cristae, electron leakage drops and reactive oxygen species decrease.
• Not a classical antioxidant — although ROS falls downstream, the primary mechanism is structural, not direct radical scavenging.

It's a fundamentally different intervention from vitamin-style antioxidants: it changes the architecture, not the atmosphere.

What Researchers Have Observed

• Primary mitochondrial myopathy. The MMPOWER trials examined SS-31 in patients with genetically confirmed mitochondrial disease, reporting improvements in exercise capacity and patient-reported outcomes in Phase 2.
• Barth syndrome. TAZPOWER studied SS-31 in Barth syndrome (a cardiolipin-remodeling disorder), with reported improvements in functional capacity and cardiac measures during open-label extension.
• Dry age-related macular degeneration. The ReCLAIM program examined SS-31 in dry AMD with geographic atrophy, reporting signals on retinal function measures.
• Heart failure with preserved ejection fraction. Earlier programs examined SS-31 in ischemia-reperfusion and heart failure, with mixed results that shifted the program toward genetic mitochondrial conditions.
• Mitochondrial aging research. Beyond the clinical programs, SS-31 is widely used as a research tool for probing the role of cardiolipin integrity in aging biology.

The Empowerment Angle: Quality of Life Research

Many people researching SS-31 aren't looking for a supplement — they're trying to build a mental model of mitochondrial biology:

• Understanding your own cellular energy — cristae, cardiolipin, ETC efficiency, and why they matter for fatigue, exercise, and aging
• Seeing aging as a biology worth engaging with, not just accepting
• Appreciating structural interventions versus chemical ones — an important distinction across pharmacology
• Tracking mitochondrial health indirectly through exercise capacity, recovery, VO2max, and perceived energy
• Contributing to scientific literacy around one of the most important organelles in medicine

The empowerment here is intellectual as much as physical: SS-31 is a window into how far peptide engineering can go when it's targeted with precision.

State of the Evidence

SS-31 has one of the more substantial clinical programs of any compound in this library.

• Phase 2/3 data published across multiple indications.
• FDA approval has not yet been obtained; Stealth BioTherapeutics' commercial trajectory has been complicated.
• As a mitochondria-targeted intervention, SS-31 occupies a distinct pharmacologic niche and is frequently cited in aging-biology research.
• Human pharmacokinetics and safety are well characterized within the trial populations studied.

This is not an obscure research chemical — it's an investigational drug with a real clinical file. That context matters when reading about it.

Approaching Research Responsibly

The most mature approach isn't hype or skepticism, but curious, methodical, well-informed engagement with the mitochondrial biology that SS-31 research has illuminated.

This entry was rewritten to help you understand both the science and the human motivation behind researching SS-31. The goal is informed curiosity and empowerment, not medical advice.

References

1. [1]Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics(2014) · doi:10.1111/bph.12461
2. [2]Karaa A et al. Randomized dose-escalation trial of elamipretide in primary mitochondrial myopathy (MMPOWER)(2018) · doi:10.1212/WNL.0000000000005641
3. [3]Reid Thompson W et al. A phase 2/3 randomized clinical trial followed by open-label extension of elamipretide for Barth syndrome (TAZPOWER)(2024)